Hemophilia Market is segmented By Disease Type (Hemophilia A, Hemophilia B, Hemophilia C, Others), By Therapy (Replacement Therapy, Gene Therapy, ITI therapy), By Product Type (Recombinant Coagulation, Factor Concentrates, Plasma-derived Coagulation, Factor Concentrates, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Hemophilia Market Size
The Global Hemophilia Market reached USD 11.7 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 18 billion by 2031. The Hemophilia Market is expected to exhibit a CAGR of 5.9% during the forecast period 2024-2031. Hemophilia is induced by a genetic deficiency of a coagulation element that delays blood clotting owing to the lack of sufficient blood-clotting proteins.
Hemophilia is generally treated employing drugs, replacement treatment, and injections of a clotting factor or plasma. Hemophilia treatment concentrates on superseding absent proteins and averting intricacies.
Hemophilia Market Scope
| Metrics | Details |
| CAGR | 5.9% |
| Size Available for Years | 2022−2031 |
| Forecast Period | 2024−2031 |
| Data Availability | Value (USD) |
| Segments Covered | Disease Type, Product Type, Therapy and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Disease Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis key Insights. |
For more Insights - Request Free Sample
Hemophilia Market Trends
The increasing research activities are driving the global hemophilia market growth in the forecast period.
The increasing research activities by key market players drive the growth of the global hemophilia market during the forecast period. For instance, in February 2022, BioMarin Pharmaceutical, a global leader in designing and manufacturing innovative biopharmaceuticals for rare conditions caused by genetic reasons, delivered positive outcomes from a two-year investigation of the Phase III GENEr8-1 analysis and an all-around safety update of valoctocogene roxaparvovec, an investigational gene therapy for the therapy of adults with extreme hemophilia A, at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).
The high treatment cost is hampering the global hemophilia market growth.
The hemophilia drugs are expensive, which restricts a large population from affording the treatment. For instance, the expense of annual drug treatment for an individual with hemophilia is around several hundred thousand USD, and for patients with the most extreme states of the disorder, the yearly therapy expenses of USD 1 million or more.
Hemophilia Market Segment Analysis
The Global Hemophilia Market is segmented based on disease type, product type, therapy, and region.
The hemophilia A diseases type segment is expected to dominate the market over the forecast period.
Owing to the high prevalence and increasing market developments, hemophilia A is estimated to hold around 48.2% of the total hemophilia treatment market by 2030. For instance, according to the NIH, Hemophilia A is the prevalent genetic condition of hemostasis, transpires in one out of 5000 men, and makes up 80% of hemophilia patients.
Hemophilia A surfaces in over 400000 males globally, most of whom stay undiagnosed in developing nations. Moreover, in 2022, Takeda Pharmaceutical Company Limited, a Japanese global pharmaceutical corporation, introduced Adynovate, a prolonged half-life recombinant Factor VIII (rFVIII) therapy for hemophilia A suffering individuals in India.
Source: DataM Intelligence Analysis (2023)
Global Hemophilia Market Geographical Share
North America holds the largest share of the global hemophilia market.
North America is estimated to hold around 40.6% of the Global Hemophilia Market owing to the high prevalence and government initiative. For instance, in August 2022, according to the U.S. Centers for Disease Control and Prevention (CDC), approximately 33,000 individuals in the U.S. had hemophilia.
Hemophilia generally involves men and individuals assigned male at birth (AMAB). Moreover, the task of the CDC’s Division of Blood Disorders is to lower the morbidity and mortality from blood conditions via a comprehensive public health approach. CDC is especially positioned to lower the public health load of bleeding conditions like hemophilia.
Source: DataM Intelligence Analysis (2023)
Hemophilia Market Key Players
The major global players in the market include Bayer AG, BioMarin Pharmaceutical, Inc., CSL Behring, Kedrion S.p.A, Novo Nordisk, Pfizer, Inc., Roche (Chugai Pharmaceutical Co.), Sanofi (Genzyme Corporation), and Takeda Pharmaceutical (Shire Plc.), Grifols among others.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine war had a negative influence on the market as because of the conflict patients from Ukraine and neighboring provinces were unable to receive care however various organizations stood up and tried to help the individuals.
For instance, the World Federation of Hemophilia teams is closely monitoring the situation to best support those who are affected via cooperating with national member organizations (NMOs), hemophilia treatment centers (HTCs), and additional stakeholders in Ukraine and neighboring nations that are influenced by the dispute.
Additionally, Russia and Ukraine are regarded as clinical trial hubs of the world, and this current circumstance is impeding the clinical research projects in these regions, thus negatively influencing the global hemophilia market growth.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession.
Artificial Intelligence Impact Analysis
AI is largely utilized in designing and developing new treatment options for hemophilia, positively impacting the global hemophilia market growth in the forthcoming years. For instance, the Duke University Durham, NC projects considered for Pfizer funding will concentrate on employing Machine Learning/Artificial Intelligence in developing treatments, emphasizing potential one-time therapies like genetic medicine/gene transfer.
Key Developments
- In July 2022, EMA instructed awarding a conditional commercializing license in the European Union (EU) for Roctavian (valoctocogene roxaparvovec) for the therapy of extreme hemophilia A in adults who lack factor VIII inhibitors (auto-antibodies elicited by the immune system making factor VIII medicines less useful) and no antibodies to adeno-associated virus serotype 5 (AAV5).
- In February 2023, the U.S. Food and Drug Administration (FDA) authorized Sanofi's ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement treatment and is meant for periodic prophylaxis and on-demand therapy to arrest bleeding attacks, and as perioperative management (surgery) for adults and children with hemophilia A.
- In March 2022, Freeline Therapeutics Holdings, a foremost biotechnology corporation concentrated on innovative liver-directed gene treatments for bleeding conditions and additional debilitating, chronic diseases, dosed the first patient in its Phase I/II B-LIEVE dose-confirmation clinical investigation of FLT180a for the therapy of hemophilia B, a debilitating genetic bleeding disease induced by a lack in the clotting factor IX protein.
Why Purchase the Report?
- To visualize the Global Hemophilia Market segmentation based on disease type, product type, therapy, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of hemophilia market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The Global Hemophilia Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
